Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.26)
# 359
Out of 4,869 analysts
77
Total ratings
57.41%
Success rate
14.23%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $32.06 | +71.55% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $25.90 | +23.55% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $126.55 | +46.19% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $20.56 | +45.91% | 1 | Mar 12, 2025 | |
| SWTX SpringWorks Therapeutics | Maintains: Outperform | $60 → $65 | $46.96 | +38.42% | 2 | Feb 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $41.73 | +19.82% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $14.29 | +249.90% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $106.53 | +17.34% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $55.00 | +90.91% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $509.72 | +130.52% | 5 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $63.00 | +34.92% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $37.14 | +136.94% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $127.04 | +117.25% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $2.61 | +1,241.00% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $289.33 | -19.81% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $68.46 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $108.50 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $29.09 | -27.81% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.20 | +619.87% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $9.99 | +2,402.50% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $0.75 | +1,233.33% | 1 | Feb 14, 2018 |
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $32.06
Upside: +71.55%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $25.90
Upside: +23.55%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $126.55
Upside: +46.19%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $20.56
Upside: +45.91%
SpringWorks Therapeutics
Feb 12, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $46.96
Upside: +38.42%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $41.73
Upside: +19.82%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $14.29
Upside: +249.90%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $106.53
Upside: +17.34%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $55.00
Upside: +90.91%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $509.72
Upside: +130.52%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $63.00
Upside: +34.92%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $37.14
Upside: +136.94%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $127.04
Upside: +117.25%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $2.61
Upside: +1,241.00%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $289.33
Upside: -19.81%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.46
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $108.50
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $29.09
Upside: -27.81%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.20
Upside: +619.87%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $9.99
Upside: +2,402.50%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $0.75
Upside: +1,233.33%